nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—Epirubicin—thyroid cancer	0.148	0.2	CbGbCtD
Ezetimibe—UGT1A1—Sorafenib—thyroid cancer	0.112	0.151	CbGbCtD
Ezetimibe—ABCG2—Vandetanib—thyroid cancer	0.102	0.138	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—thyroid cancer	0.0908	0.123	CbGbCtD
Ezetimibe—ABCC2—Sorafenib—thyroid cancer	0.068	0.092	CbGbCtD
Ezetimibe—ABCG2—Sorafenib—thyroid cancer	0.0615	0.0832	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—thyroid cancer	0.0413	0.0558	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—thyroid cancer	0.0373	0.0505	CbGbCtD
Ezetimibe—ABCB1—Sorafenib—thyroid cancer	0.0222	0.03	CbGbCtD
Ezetimibe—CYP3A4—Vandetanib—thyroid cancer	0.022	0.0298	CbGbCtD
Ezetimibe—ABCB1—Doxorubicin—thyroid cancer	0.0134	0.0182	CbGbCtD
Ezetimibe—CYP3A4—Sorafenib—thyroid cancer	0.0133	0.018	CbGbCtD
Ezetimibe—CYP3A4—Doxorubicin—thyroid cancer	0.00806	0.0109	CbGbCtD
Ezetimibe—SOAT1—saliva-secreting gland—thyroid cancer	0.00205	0.135	CbGeAlD
Ezetimibe—ANPEP—saliva-secreting gland—thyroid cancer	0.00196	0.129	CbGeAlD
Ezetimibe—ANPEP—trachea—thyroid cancer	0.00151	0.0993	CbGeAlD
Ezetimibe—SOAT1—thyroid gland—thyroid cancer	0.00125	0.0821	CbGeAlD
Ezetimibe—ANPEP—thyroid gland—thyroid cancer	0.0012	0.0785	CbGeAlD
Ezetimibe—SOAT1—head—thyroid cancer	0.00111	0.0729	CbGeAlD
Ezetimibe—ANPEP—head—thyroid cancer	0.00106	0.0697	CbGeAlD
Ezetimibe—Thrombocytopenia—Vandetanib—thyroid cancer	0.000818	0.00511	CcSEcCtD
Ezetimibe—Skin disorder—Vandetanib—thyroid cancer	0.000811	0.00506	CcSEcCtD
Ezetimibe—Connective tissue disorder—Sorafenib—thyroid cancer	0.000779	0.00487	CcSEcCtD
Ezetimibe—SOAT1—lymph node—thyroid cancer	0.000777	0.051	CbGeAlD
Ezetimibe—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000761	0.00475	CcSEcCtD
Ezetimibe—Insomnia—Vandetanib—thyroid cancer	0.000755	0.00472	CcSEcCtD
Ezetimibe—Paraesthesia—Vandetanib—thyroid cancer	0.00075	0.00468	CcSEcCtD
Ezetimibe—Erythema multiforme—Sorafenib—thyroid cancer	0.00075	0.00468	CcSEcCtD
Ezetimibe—Dyspnoea—Vandetanib—thyroid cancer	0.000745	0.00465	CcSEcCtD
Ezetimibe—ANPEP—lymph node—thyroid cancer	0.000743	0.0488	CbGeAlD
Ezetimibe—Flushing—Sorafenib—thyroid cancer	0.000736	0.00459	CcSEcCtD
Ezetimibe—Dyspepsia—Vandetanib—thyroid cancer	0.000735	0.00459	CcSEcCtD
Ezetimibe—Decreased appetite—Vandetanib—thyroid cancer	0.000726	0.00453	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000721	0.0045	CcSEcCtD
Ezetimibe—Fatigue—Vandetanib—thyroid cancer	0.00072	0.0045	CcSEcCtD
Ezetimibe—Angiopathy—Sorafenib—thyroid cancer	0.000719	0.00449	CcSEcCtD
Ezetimibe—Immune system disorder—Sorafenib—thyroid cancer	0.000716	0.00447	CcSEcCtD
Ezetimibe—Mediastinal disorder—Sorafenib—thyroid cancer	0.000715	0.00446	CcSEcCtD
Ezetimibe—Constipation—Vandetanib—thyroid cancer	0.000714	0.00446	CcSEcCtD
Ezetimibe—Pain—Vandetanib—thyroid cancer	0.000714	0.00446	CcSEcCtD
Ezetimibe—Alopecia—Sorafenib—thyroid cancer	0.000701	0.00437	CcSEcCtD
Ezetimibe—Mental disorder—Sorafenib—thyroid cancer	0.000695	0.00434	CcSEcCtD
Ezetimibe—Erythema—Sorafenib—thyroid cancer	0.00069	0.00431	CcSEcCtD
Ezetimibe—Malnutrition—Sorafenib—thyroid cancer	0.00069	0.00431	CcSEcCtD
Ezetimibe—Neoplasm malignant—Epirubicin—thyroid cancer	0.000683	0.00427	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000683	0.00426	CcSEcCtD
Ezetimibe—Muscle spasms—Sorafenib—thyroid cancer	0.000664	0.00414	CcSEcCtD
Ezetimibe—Abdominal pain—Vandetanib—thyroid cancer	0.00066	0.00412	CcSEcCtD
Ezetimibe—Body temperature increased—Vandetanib—thyroid cancer	0.00066	0.00412	CcSEcCtD
Ezetimibe—Bone disorder—Epirubicin—thyroid cancer	0.000646	0.00403	CcSEcCtD
Ezetimibe—Viral infection—Epirubicin—thyroid cancer	0.000646	0.00403	CcSEcCtD
Ezetimibe—Anaemia—Sorafenib—thyroid cancer	0.000638	0.00398	CcSEcCtD
Ezetimibe—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000632	0.00395	CcSEcCtD
Ezetimibe—Angioedema—Sorafenib—thyroid cancer	0.000631	0.00394	CcSEcCtD
Ezetimibe—Cough—Sorafenib—thyroid cancer	0.000602	0.00376	CcSEcCtD
Ezetimibe—Inflammation—Epirubicin—thyroid cancer	0.000602	0.00376	CcSEcCtD
Ezetimibe—Asthenia—Vandetanib—thyroid cancer	0.000599	0.00374	CcSEcCtD
Ezetimibe—Viral infection—Doxorubicin—thyroid cancer	0.000598	0.00373	CcSEcCtD
Ezetimibe—Bone disorder—Doxorubicin—thyroid cancer	0.000598	0.00373	CcSEcCtD
Ezetimibe—ABCC3—thyroid gland—thyroid cancer	0.000596	0.0392	CbGeAlD
Ezetimibe—Hypertension—Sorafenib—thyroid cancer	0.000596	0.00372	CcSEcCtD
Ezetimibe—Pruritus—Vandetanib—thyroid cancer	0.000591	0.00369	CcSEcCtD
Ezetimibe—Neck pain—Epirubicin—thyroid cancer	0.000591	0.00369	CcSEcCtD
Ezetimibe—Arthralgia—Sorafenib—thyroid cancer	0.000588	0.00367	CcSEcCtD
Ezetimibe—Myalgia—Sorafenib—thyroid cancer	0.000588	0.00367	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000584	0.00364	CcSEcCtD
Ezetimibe—Hepatocellular injury—Epirubicin—thyroid cancer	0.000584	0.00364	CcSEcCtD
Ezetimibe—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000584	0.00364	CcSEcCtD
Ezetimibe—Dry mouth—Sorafenib—thyroid cancer	0.000575	0.00359	CcSEcCtD
Ezetimibe—Diarrhoea—Vandetanib—thyroid cancer	0.000571	0.00357	CcSEcCtD
Ezetimibe—ABCG2—saliva-secreting gland—thyroid cancer	0.000569	0.0374	CbGeAlD
Ezetimibe—Anaphylactic shock—Sorafenib—thyroid cancer	0.000563	0.00352	CcSEcCtD
Ezetimibe—Infection—Sorafenib—thyroid cancer	0.00056	0.00349	CcSEcCtD
Ezetimibe—Inflammation—Doxorubicin—thyroid cancer	0.000557	0.00348	CcSEcCtD
Ezetimibe—Nervous system disorder—Sorafenib—thyroid cancer	0.000553	0.00345	CcSEcCtD
Ezetimibe—Dizziness—Vandetanib—thyroid cancer	0.000552	0.00345	CcSEcCtD
Ezetimibe—Thrombocytopenia—Sorafenib—thyroid cancer	0.000552	0.00344	CcSEcCtD
Ezetimibe—Skin disorder—Sorafenib—thyroid cancer	0.000547	0.00342	CcSEcCtD
Ezetimibe—Neck pain—Doxorubicin—thyroid cancer	0.000547	0.00341	CcSEcCtD
Ezetimibe—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00054	0.00337	CcSEcCtD
Ezetimibe—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00054	0.00337	CcSEcCtD
Ezetimibe—Vomiting—Vandetanib—thyroid cancer	0.000531	0.00332	CcSEcCtD
Ezetimibe—ABCC3—head—thyroid cancer	0.000529	0.0347	CbGeAlD
Ezetimibe—Rash—Vandetanib—thyroid cancer	0.000527	0.00329	CcSEcCtD
Ezetimibe—Dermatitis—Vandetanib—thyroid cancer	0.000526	0.00328	CcSEcCtD
Ezetimibe—Headache—Vandetanib—thyroid cancer	0.000523	0.00327	CcSEcCtD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000517	0.00605	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—NDUFA13—thyroid cancer	0.000516	0.00604	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000513	0.0032	CcSEcCtD
Ezetimibe—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000509	0.00595	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CHST14—thyroid cancer	0.000504	0.0059	CbGpPWpGaD
Ezetimibe—Dyspnoea—Sorafenib—thyroid cancer	0.000502	0.00314	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—CP—thyroid cancer	0.000498	0.00583	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000498	0.00583	CbGpPWpGaD
Ezetimibe—Nausea—Vandetanib—thyroid cancer	0.000496	0.0031	CcSEcCtD
Ezetimibe—Dyspepsia—Sorafenib—thyroid cancer	0.000496	0.0031	CcSEcCtD
Ezetimibe—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000492	0.00576	CbGpPWpGaD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00049	0.00574	CbGpPWpGaD
Ezetimibe—Decreased appetite—Sorafenib—thyroid cancer	0.00049	0.00306	CcSEcCtD
Ezetimibe—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000487	0.00304	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000486	0.00304	CcSEcCtD
Ezetimibe—Fatigue—Sorafenib—thyroid cancer	0.000486	0.00303	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—CHST14—thyroid cancer	0.000485	0.00568	CbGpPWpGaD
Ezetimibe—UGT2B15—Biological oxidations—RXRA—thyroid cancer	0.000484	0.00566	CbGpPWpGaD
Ezetimibe—Photosensitivity—Epirubicin—thyroid cancer	0.000482	0.00301	CcSEcCtD
Ezetimibe—Constipation—Sorafenib—thyroid cancer	0.000482	0.00301	CcSEcCtD
Ezetimibe—Pain—Sorafenib—thyroid cancer	0.000482	0.00301	CcSEcCtD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—CP—thyroid cancer	0.00048	0.00561	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00048	0.00561	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000472	0.00552	CbGpPWpGaD
Ezetimibe—Hepatic failure—Epirubicin—thyroid cancer	0.000471	0.00294	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—KRAS—thyroid cancer	0.000471	0.00551	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000461	0.00288	CcSEcCtD
Ezetimibe—Hot flush—Epirubicin—thyroid cancer	0.000453	0.00283	CcSEcCtD
Ezetimibe—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000451	0.00281	CcSEcCtD
Ezetimibe—Menopausal symptoms—Epirubicin—thyroid cancer	0.000449	0.0028	CcSEcCtD
Ezetimibe—Urticaria—Sorafenib—thyroid cancer	0.000448	0.00279	CcSEcCtD
Ezetimibe—Photosensitivity—Doxorubicin—thyroid cancer	0.000446	0.00279	CcSEcCtD
Ezetimibe—Body temperature increased—Sorafenib—thyroid cancer	0.000445	0.00278	CcSEcCtD
Ezetimibe—Abdominal pain—Sorafenib—thyroid cancer	0.000445	0.00278	CcSEcCtD
Ezetimibe—Hepatic failure—Doxorubicin—thyroid cancer	0.000436	0.00272	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000435	0.00509	CbGpPWpGaD
Ezetimibe—Pain in extremity—Epirubicin—thyroid cancer	0.000424	0.00264	CcSEcCtD
Ezetimibe—Hot flush—Doxorubicin—thyroid cancer	0.000419	0.00262	CcSEcCtD
Ezetimibe—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000415	0.00259	CcSEcCtD
Ezetimibe—Hypersensitivity—Sorafenib—thyroid cancer	0.000415	0.00259	CcSEcCtD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000408	0.00477	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—HPGD—thyroid cancer	0.000406	0.00476	CbGpPWpGaD
Ezetimibe—Asthenia—Sorafenib—thyroid cancer	0.000404	0.00252	CcSEcCtD
Ezetimibe—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000403	0.00472	CbGpPWpGaD
Ezetimibe—ANPEP—C-MYB transcription factor network—HRAS—thyroid cancer	0.0004	0.00469	CbGpPWpGaD
Ezetimibe—Pruritus—Sorafenib—thyroid cancer	0.000399	0.00249	CcSEcCtD
Ezetimibe—Pain in extremity—Doxorubicin—thyroid cancer	0.000392	0.00245	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—HPGD—thyroid cancer	0.000391	0.00458	CbGpPWpGaD
Ezetimibe—Liver function test abnormal—Epirubicin—thyroid cancer	0.000391	0.00244	CcSEcCtD
Ezetimibe—Diarrhoea—Sorafenib—thyroid cancer	0.000385	0.00241	CcSEcCtD
Ezetimibe—Breast disorder—Epirubicin—thyroid cancer	0.000383	0.00239	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000381	0.00238	CcSEcCtD
Ezetimibe—Nasopharyngitis—Epirubicin—thyroid cancer	0.000379	0.00237	CcSEcCtD
Ezetimibe—Gastritis—Epirubicin—thyroid cancer	0.000375	0.00234	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000374	0.00233	CcSEcCtD
Ezetimibe—Muscular weakness—Epirubicin—thyroid cancer	0.000374	0.00233	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000373	0.00437	CbGpPWpGaD
Ezetimibe—Dizziness—Sorafenib—thyroid cancer	0.000373	0.00233	CcSEcCtD
Ezetimibe—ABCC3—lymph node—thyroid cancer	0.00037	0.0243	CbGeAlD
Ezetimibe—Influenza—Epirubicin—thyroid cancer	0.000366	0.00229	CcSEcCtD
Ezetimibe—Eosinophilia—Epirubicin—thyroid cancer	0.000363	0.00226	CcSEcCtD
Ezetimibe—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000362	0.00226	CcSEcCtD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000359	0.0042	CbGpPWpGaD
Ezetimibe—Pancreatitis—Epirubicin—thyroid cancer	0.000359	0.00224	CcSEcCtD
Ezetimibe—Vomiting—Sorafenib—thyroid cancer	0.000358	0.00224	CcSEcCtD
Ezetimibe—Rash—Sorafenib—thyroid cancer	0.000355	0.00222	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—MINPP1—thyroid cancer	0.000355	0.00416	CbGpPWpGaD
Ezetimibe—Dermatitis—Sorafenib—thyroid cancer	0.000355	0.00222	CcSEcCtD
Ezetimibe—Breast disorder—Doxorubicin—thyroid cancer	0.000354	0.00221	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000353	0.0022	CcSEcCtD
Ezetimibe—Headache—Sorafenib—thyroid cancer	0.000353	0.0022	CcSEcCtD
Ezetimibe—UGT1A3—NRF2 pathway—SLC5A5—thyroid cancer	0.000351	0.00411	CbGpPWpGaD
Ezetimibe—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000351	0.00219	CcSEcCtD
Ezetimibe—ABCG2—thyroid gland—thyroid cancer	0.000347	0.0228	CbGeAlD
Ezetimibe—Gastritis—Doxorubicin—thyroid cancer	0.000347	0.00217	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—thyroid cancer	0.000346	0.00216	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000346	0.00216	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00034	0.00212	CcSEcCtD
Ezetimibe—Influenza—Doxorubicin—thyroid cancer	0.000339	0.00212	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—thyroid cancer	0.000335	0.00209	CcSEcCtD
Ezetimibe—Nausea—Sorafenib—thyroid cancer	0.000335	0.00209	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000334	0.00209	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—thyroid cancer	0.000332	0.00207	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00033	0.00386	CbGpPWpGaD
Ezetimibe—Infestation NOS—Epirubicin—thyroid cancer	0.000326	0.00204	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—thyroid cancer	0.000326	0.00204	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00032	0.002	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—thyroid cancer	0.000318	0.00199	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000317	0.00371	CbGpPWpGaD
Ezetimibe—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000315	0.00369	CbGpPWpGaD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000315	0.00197	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000313	0.00367	CbGpPWpGaD
Ezetimibe—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000309	0.00193	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000309	0.00193	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—TPR—thyroid cancer	0.000308	0.0036	CbGpPWpGaD
Ezetimibe—Sinusitis—Epirubicin—thyroid cancer	0.000306	0.00191	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—PRKAR1A—thyroid cancer	0.000303	0.00355	CbGpPWpGaD
Ezetimibe—Infestation—Doxorubicin—thyroid cancer	0.000302	0.00189	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—thyroid cancer	0.000302	0.00189	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—NDUFA13—thyroid cancer	0.000302	0.00354	CbGpPWpGaD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000302	0.00353	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—SLC5A5—thyroid cancer	0.000299	0.0035	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—SLC5A5—thyroid cancer	0.000299	0.0035	CbGpPWpGaD
Ezetimibe—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000296	0.00185	CcSEcCtD
Ezetimibe—ABCC2—lymph node—thyroid cancer	0.000296	0.0194	CbGeAlD
Ezetimibe—UGT1A3—NRF2 pathway—RXRA—thyroid cancer	0.000295	0.00346	CbGpPWpGaD
Ezetimibe—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000295	0.00345	CbGpPWpGaD
Ezetimibe—Jaundice—Doxorubicin—thyroid cancer	0.000294	0.00184	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—thyroid cancer	0.000293	0.00183	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—thyroid cancer	0.000291	0.00182	CcSEcCtD
Ezetimibe—Oedema peripheral—Epirubicin—thyroid cancer	0.000289	0.0018	CcSEcCtD
Ezetimibe—Connective tissue disorder—Epirubicin—thyroid cancer	0.000288	0.0018	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000286	0.00178	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—CHST14—thyroid cancer	0.000284	0.00332	CbGpPWpGaD
Ezetimibe—Sinusitis—Doxorubicin—thyroid cancer	0.000283	0.00177	CcSEcCtD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000281	0.00329	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00028	0.00327	CbGpPWpGaD
Ezetimibe—Erythema multiforme—Epirubicin—thyroid cancer	0.000277	0.00173	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000275	0.00321	CbGpPWpGaD
Ezetimibe—Flushing—Epirubicin—thyroid cancer	0.000272	0.0017	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—thyroid cancer	0.000271	0.00169	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—thyroid cancer	0.000269	0.00168	CcSEcCtD
Ezetimibe—Oedema peripheral—Doxorubicin—thyroid cancer	0.000267	0.00167	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000266	0.00166	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—thyroid cancer	0.000266	0.00166	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—thyroid cancer	0.000265	0.00165	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—thyroid cancer	0.000264	0.00165	CcSEcCtD
Ezetimibe—UGT1A3—Biological oxidations—RXRA—thyroid cancer	0.000259	0.00303	CbGpPWpGaD
Ezetimibe—Alopecia—Epirubicin—thyroid cancer	0.000259	0.00162	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—thyroid cancer	0.000257	0.0016	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—thyroid cancer	0.000256	0.0016	CcSEcCtD
Ezetimibe—UGT1A3—NRF2 pathway—NRG1—thyroid cancer	0.000255	0.00299	CbGpPWpGaD
Ezetimibe—Erythema—Epirubicin—thyroid cancer	0.000255	0.00159	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—thyroid cancer	0.000255	0.00159	CcSEcCtD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000254	0.00297	CbGpPWpGaD
Ezetimibe—Flushing—Doxorubicin—thyroid cancer	0.000252	0.00157	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—thyroid cancer	0.000251	0.00157	CcSEcCtD
Ezetimibe—ABCC3—NRF2 pathway—RXRA—thyroid cancer	0.000251	0.00294	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—RXRA—thyroid cancer	0.000251	0.00294	CbGpPWpGaD
Ezetimibe—Back pain—Epirubicin—thyroid cancer	0.000247	0.00154	CcSEcCtD
Ezetimibe—Angiopathy—Doxorubicin—thyroid cancer	0.000246	0.00154	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—thyroid cancer	0.000245	0.00153	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—thyroid cancer	0.000245	0.00153	CcSEcCtD
Ezetimibe—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000244	0.00153	CcSEcCtD
Ezetimibe—ABCC3—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000244	0.00285	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—SLC5A5—thyroid cancer	0.000243	0.00284	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000243	0.00284	CbGpPWpGaD
Ezetimibe—Alopecia—Doxorubicin—thyroid cancer	0.00024	0.0015	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—thyroid cancer	0.000238	0.00148	CcSEcCtD
Ezetimibe—ABCC2—NRF2 pathway—SLC5A5—thyroid cancer	0.000237	0.00277	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Epirubicin—thyroid cancer	0.000237	0.00148	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—thyroid cancer	0.000236	0.00147	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—thyroid cancer	0.000236	0.00147	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—thyroid cancer	0.000236	0.00147	CcSEcCtD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000234	0.00274	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—TPR—thyroid cancer	0.000233	0.00273	CbGpPWpGaD
Ezetimibe—Flatulence—Doxorubicin—thyroid cancer	0.000233	0.00145	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—SLC5A5—thyroid cancer	0.000231	0.0027	CbGpPWpGaD
Ezetimibe—Malaise—Epirubicin—thyroid cancer	0.00023	0.00144	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—PRKAR1A—thyroid cancer	0.00023	0.00269	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—HPGD—thyroid cancer	0.000229	0.00268	CbGpPWpGaD
Ezetimibe—Back pain—Doxorubicin—thyroid cancer	0.000228	0.00143	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—thyroid cancer	0.000227	0.00142	CcSEcCtD
Ezetimibe—Palpitations—Epirubicin—thyroid cancer	0.000225	0.00141	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—TPR—thyroid cancer	0.000225	0.00263	CbGpPWpGaD
Ezetimibe—Cough—Epirubicin—thyroid cancer	0.000223	0.00139	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—PRKAR1A—thyroid cancer	0.000221	0.00259	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.00022	0.00258	CbGpPWpGaD
Ezetimibe—Hypertension—Epirubicin—thyroid cancer	0.00022	0.00138	CcSEcCtD
Ezetimibe—UGT2B7—Biological oxidations—RXRA—thyroid cancer	0.00022	0.00258	CbGpPWpGaD
Ezetimibe—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000219	0.00137	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—thyroid cancer	0.000218	0.00136	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—thyroid cancer	0.000217	0.00136	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—thyroid cancer	0.000217	0.00136	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—thyroid cancer	0.000217	0.00136	CcSEcCtD
Ezetimibe—UGT2B7—NRF2 pathway—NRG1—thyroid cancer	0.000217	0.00254	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—NRG1—thyroid cancer	0.000217	0.00254	CbGpPWpGaD
Ezetimibe—ABCB1—trachea—thyroid cancer	0.000217	0.0142	CbGeAlD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000216	0.00253	CbGpPWpGaD
Ezetimibe—ABCG2—lymph node—thyroid cancer	0.000216	0.0142	CbGeAlD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000216	0.00135	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—thyroid cancer	0.000215	0.00134	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—thyroid cancer	0.000213	0.00133	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—thyroid cancer	0.000212	0.00133	CcSEcCtD
Ezetimibe—Confusional state—Epirubicin—thyroid cancer	0.00021	0.00131	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—thyroid cancer	0.000209	0.0013	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—thyroid cancer	0.000208	0.0013	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000208	0.00244	CbGpPWpGaD
Ezetimibe—Infection—Epirubicin—thyroid cancer	0.000207	0.00129	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—thyroid cancer	0.000206	0.00129	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—thyroid cancer	0.000204	0.00127	CcSEcCtD
Ezetimibe—UGT1A1—NRF2 pathway—RXRA—thyroid cancer	0.000204	0.00239	CbGpPWpGaD
Ezetimibe—Thrombocytopenia—Epirubicin—thyroid cancer	0.000204	0.00127	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—thyroid cancer	0.000204	0.00127	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—thyroid cancer	0.000202	0.00126	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—thyroid cancer	0.000201	0.00125	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—thyroid cancer	0.000201	0.00125	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—thyroid cancer	0.000201	0.00125	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.0002	0.00235	CbGpPWpGaD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0002	0.00125	CcSEcCtD
Ezetimibe—ABCC2—NRF2 pathway—RXRA—thyroid cancer	0.000199	0.00233	CbGpPWpGaD
Ezetimibe—Discomfort—Doxorubicin—thyroid cancer	0.000199	0.00124	CcSEcCtD
Ezetimibe—Dry mouth—Doxorubicin—thyroid cancer	0.000197	0.00123	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—thyroid cancer	0.000194	0.00121	CcSEcCtD
Ezetimibe—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000194	0.00227	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—RXRA—thyroid cancer	0.000194	0.00227	CbGpPWpGaD
Ezetimibe—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000193	0.0012	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—thyroid cancer	0.000191	0.00119	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—MINPP1—thyroid cancer	0.00019	0.00223	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00019	0.00118	CcSEcCtD
Ezetimibe—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00019	0.00222	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Doxorubicin—thyroid cancer	0.000189	0.00118	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000189	0.00118	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000188	0.00221	CbGpPWpGaD
Ezetimibe—Insomnia—Epirubicin—thyroid cancer	0.000188	0.00118	CcSEcCtD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000187	0.00219	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000187	0.00219	CbGpPWpGaD
Ezetimibe—Skin disorder—Doxorubicin—thyroid cancer	0.000187	0.00117	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—thyroid cancer	0.000187	0.00117	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—thyroid cancer	0.000186	0.00116	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—thyroid cancer	0.000183	0.00114	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—thyroid cancer	0.000181	0.00113	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00018	0.00112	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—thyroid cancer	0.00018	0.00112	CcSEcCtD
Ezetimibe—UGT1A1—Biological oxidations—RXRA—thyroid cancer	0.000179	0.00209	CbGpPWpGaD
Ezetimibe—Pain—Epirubicin—thyroid cancer	0.000178	0.00111	CcSEcCtD
Ezetimibe—Constipation—Epirubicin—thyroid cancer	0.000178	0.00111	CcSEcCtD
Ezetimibe—UGT1A1—NRF2 pathway—NRG1—thyroid cancer	0.000176	0.00207	CbGpPWpGaD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000176	0.0011	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—SLC5A5—thyroid cancer	0.000175	0.00205	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000174	0.00204	CbGpPWpGaD
Ezetimibe—Insomnia—Doxorubicin—thyroid cancer	0.000174	0.00109	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—thyroid cancer	0.000173	0.00108	CcSEcCtD
Ezetimibe—ABCC2—NRF2 pathway—NRG1—thyroid cancer	0.000172	0.00201	CbGpPWpGaD
Ezetimibe—Dyspnoea—Doxorubicin—thyroid cancer	0.000172	0.00107	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—thyroid cancer	0.000172	0.00107	CcSEcCtD
Ezetimibe—ABCB1—thyroid gland—thyroid cancer	0.000171	0.0112	CbGeAlD
Ezetimibe—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000171	0.00201	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00017	0.00106	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—thyroid cancer	0.00017	0.00106	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—SLC5A5—thyroid cancer	0.000168	0.00197	CbGpPWpGaD
Ezetimibe—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000168	0.00197	CbGpPWpGaD
Ezetimibe—Decreased appetite—Doxorubicin—thyroid cancer	0.000167	0.00105	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000166	0.00104	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—thyroid cancer	0.000166	0.00104	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—thyroid cancer	0.000165	0.00103	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—thyroid cancer	0.000165	0.00103	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—thyroid cancer	0.000165	0.00103	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—thyroid cancer	0.000165	0.00103	CcSEcCtD
Ezetimibe—Body temperature increased—Epirubicin—thyroid cancer	0.000165	0.00103	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000164	0.00192	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—NDUFA13—thyroid cancer	0.000162	0.00189	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—MINPP1—thyroid cancer	0.000162	0.00189	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—MINPP1—thyroid cancer	0.000162	0.00189	CbGpPWpGaD
Ezetimibe—Feeling abnormal—Doxorubicin—thyroid cancer	0.000159	0.000991	CcSEcCtD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000158	0.00184	CbGpPWpGaD
Ezetimibe—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000158	0.000984	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—thyroid cancer	0.000153	0.000958	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—thyroid cancer	0.000153	0.000956	CcSEcCtD
Ezetimibe—Abdominal pain—Doxorubicin—thyroid cancer	0.000152	0.000951	CcSEcCtD
Ezetimibe—Body temperature increased—Doxorubicin—thyroid cancer	0.000152	0.000951	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—CHST14—thyroid cancer	0.000152	0.00178	CbGpPWpGaD
Ezetimibe—ABCB1—head—thyroid cancer	0.000152	0.00998	CbGeAlD
Ezetimibe—Asthenia—Epirubicin—thyroid cancer	0.000149	0.000933	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—thyroid cancer	0.000147	0.00092	CcSEcCtD
Ezetimibe—ABCG8—Metabolism—RXRA—thyroid cancer	0.000147	0.00172	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000143	0.00167	CbGpPWpGaD
Ezetimibe—Diarrhoea—Epirubicin—thyroid cancer	0.000142	0.000889	CcSEcCtD
Ezetimibe—Hypersensitivity—Doxorubicin—thyroid cancer	0.000142	0.000886	CcSEcCtD
Ezetimibe—ABCG5—Metabolism—RXRA—thyroid cancer	0.000141	0.00165	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00014	0.00164	CbGpPWpGaD
Ezetimibe—Asthenia—Doxorubicin—thyroid cancer	0.000138	0.000863	CcSEcCtD
Ezetimibe—Dizziness—Epirubicin—thyroid cancer	0.000138	0.00086	CcSEcCtD
Ezetimibe—ABCC3—Metabolism—NDUFA13—thyroid cancer	0.000138	0.00161	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NDUFA13—thyroid cancer	0.000138	0.00161	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000137	0.00161	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000137	0.00161	CbGpPWpGaD
Ezetimibe—Pruritus—Doxorubicin—thyroid cancer	0.000136	0.000851	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—thyroid cancer	0.000132	0.000827	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—thyroid cancer	0.000132	0.000823	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—TPR—thyroid cancer	0.000131	0.00154	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—MINPP1—thyroid cancer	0.000131	0.00154	CbGpPWpGaD
Ezetimibe—Rash—Epirubicin—thyroid cancer	0.000131	0.00082	CcSEcCtD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000131	0.00154	CbGpPWpGaD
Ezetimibe—Dermatitis—Epirubicin—thyroid cancer	0.000131	0.000819	CcSEcCtD
Ezetimibe—Headache—Epirubicin—thyroid cancer	0.00013	0.000814	CcSEcCtD
Ezetimibe—UGT2B15—Metabolism—PRKAR1A—thyroid cancer	0.000129	0.00151	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CHST14—thyroid cancer	0.000129	0.00151	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CHST14—thyroid cancer	0.000129	0.00151	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—CP—thyroid cancer	0.000128	0.0015	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000128	0.0015	CbGpPWpGaD
Ezetimibe—Dizziness—Doxorubicin—thyroid cancer	0.000127	0.000795	CcSEcCtD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000126	0.00147	CbGpPWpGaD
Ezetimibe—Nausea—Epirubicin—thyroid cancer	0.000124	0.000772	CcSEcCtD
Ezetimibe—UGT1A3—Metabolism—HPGD—thyroid cancer	0.000123	0.00144	CbGpPWpGaD
Ezetimibe—Vomiting—Doxorubicin—thyroid cancer	0.000122	0.000765	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism—PPARG—thyroid cancer	0.000122	0.00143	CbGpPWpGaD
Ezetimibe—Rash—Doxorubicin—thyroid cancer	0.000121	0.000758	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—thyroid cancer	0.000121	0.000758	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—thyroid cancer	0.000121	0.000754	CcSEcCtD
Ezetimibe—SLCO1B1—Metabolism—MINPP1—thyroid cancer	0.00012	0.00141	CbGpPWpGaD
Ezetimibe—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000117	0.00137	CbGpPWpGaD
Ezetimibe—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000117	0.00137	CbGpPWpGaD
Ezetimibe—Nausea—Doxorubicin—thyroid cancer	0.000114	0.000714	CcSEcCtD
Ezetimibe—UGT1A1—Metabolism—NDUFA13—thyroid cancer	0.000112	0.00131	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—MINPP1—thyroid cancer	0.000112	0.00131	CbGpPWpGaD
Ezetimibe—ABCB1—lymph node—thyroid cancer	0.000106	0.00699	CbGeAlD
Ezetimibe—UGT1A1—Metabolism—CHST14—thyroid cancer	0.000105	0.00123	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—HPGD—thyroid cancer	0.000104	0.00122	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—HPGD—thyroid cancer	0.000104	0.00122	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NDUFA13—thyroid cancer	0.000102	0.0012	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000101	0.00119	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000101	0.00119	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.97e-05	0.00117	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—SLC5A5—thyroid cancer	9.84e-05	0.00115	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CHST14—thyroid cancer	9.63e-05	0.00113	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PTGS2—thyroid cancer	9.62e-05	0.00113	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.57e-05	0.00112	CbGpPWpGaD
Ezetimibe—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.52e-05	0.00111	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—TPR—thyroid cancer	9.52e-05	0.00111	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—CP—thyroid cancer	9.52e-05	0.00111	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NDUFA13—thyroid cancer	9.49e-05	0.00111	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.37e-05	0.0011	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PPARG—thyroid cancer	9.27e-05	0.00108	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PPARG—thyroid cancer	8.92e-05	0.00104	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CHST14—thyroid cancer	8.92e-05	0.00104	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	8.82e-05	0.00103	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	8.82e-05	0.00103	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.67e-05	0.00102	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HPGD—thyroid cancer	8.47e-05	0.000992	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.46e-05	0.00099	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—PTEN—thyroid cancer	8.39e-05	0.000982	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—RXRA—thyroid cancer	8.27e-05	0.000968	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	8.16e-05	0.000955	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.04e-05	0.000941	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HPGD—thyroid cancer	7.76e-05	0.000909	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.59e-05	0.000888	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	7.55e-05	0.000884	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTGS2—thyroid cancer	7.29e-05	0.000853	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HPGD—thyroid cancer	7.19e-05	0.000841	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.13e-05	0.000834	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—TPR—thyroid cancer	7.04e-05	0.000824	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTGS2—thyroid cancer	7.02e-05	0.000822	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	6.93e-05	0.000811	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.6e-05	0.000772	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.38e-05	0.000746	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—PTEN—thyroid cancer	6.36e-05	0.000744	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.3e-05	0.000737	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—PTEN—thyroid cancer	6.12e-05	0.000716	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—MINPP1—thyroid cancer	6.03e-05	0.000706	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—TPR—thyroid cancer	5.99e-05	0.000701	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—TPR—thyroid cancer	5.99e-05	0.000701	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.99e-05	0.000701	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PRKAR1A—thyroid cancer	5.89e-05	0.00069	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	5.89e-05	0.00069	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.54e-05	0.000649	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.34e-05	0.000625	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—SLC5A5—thyroid cancer	5.27e-05	0.000617	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PPARG—thyroid cancer	5.22e-05	0.000611	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NDUFA13—thyroid cancer	5.13e-05	0.0006	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.06e-05	0.000592	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—TPR—thyroid cancer	4.87e-05	0.00057	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—AKT1—thyroid cancer	4.84e-05	0.000566	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CHST14—thyroid cancer	4.82e-05	0.000564	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	4.79e-05	0.00056	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.77e-05	0.000558	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.77e-05	0.000558	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.69e-05	0.000549	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—SLC5A5—thyroid cancer	4.48e-05	0.000525	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—SLC5A5—thyroid cancer	4.48e-05	0.000525	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—TPR—thyroid cancer	4.46e-05	0.000522	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—RXRA—thyroid cancer	4.43e-05	0.000518	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4.41e-05	0.000516	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	4.39e-05	0.000513	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.2e-05	0.000492	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—TPR—thyroid cancer	4.13e-05	0.000483	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTGS2—thyroid cancer	4.11e-05	0.000481	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PRKAR1A—thyroid cancer	4.06e-05	0.000475	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.98e-05	0.000465	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HPGD—thyroid cancer	3.89e-05	0.000455	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—RXRA—thyroid cancer	3.77e-05	0.000441	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—RXRA—thyroid cancer	3.77e-05	0.000441	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.75e-05	0.000439	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.72e-05	0.000435	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—AKT1—thyroid cancer	3.66e-05	0.000429	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.66e-05	0.000429	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—SLC5A5—thyroid cancer	3.64e-05	0.000426	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—PTEN—thyroid cancer	3.58e-05	0.000419	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.57e-05	0.000418	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—AKT1—thyroid cancer	3.53e-05	0.000413	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.39e-05	0.000397	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	3.34e-05	0.000391	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.27e-05	0.000383	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.16e-05	0.00037	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.13e-05	0.000366	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—SLC5A5—thyroid cancer	3.09e-05	0.000362	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—RXRA—thyroid cancer	3.06e-05	0.000358	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3e-05	0.000351	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CHST14—thyroid cancer	2.97e-05	0.000348	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—RXRA—thyroid cancer	2.8e-05	0.000328	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PPARG—thyroid cancer	2.8e-05	0.000327	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.73e-05	0.000319	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—RXRA—thyroid cancer	2.6e-05	0.000304	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.51e-05	0.000294	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HPGD—thyroid cancer	2.39e-05	0.00028	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PPARG—thyroid cancer	2.38e-05	0.000278	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PPARG—thyroid cancer	2.38e-05	0.000278	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—TPR—thyroid cancer	2.23e-05	0.000261	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.23e-05	0.000261	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTGS2—thyroid cancer	2.2e-05	0.000258	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.2e-05	0.000257	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—AKT1—thyroid cancer	2.06e-05	0.000242	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PPARG—thyroid cancer	1.93e-05	0.000226	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—PTEN—thyroid cancer	1.92e-05	0.000225	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.88e-05	0.000221	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTGS2—thyroid cancer	1.87e-05	0.000219	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.87e-05	0.000219	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PPARG—thyroid cancer	1.77e-05	0.000207	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.67e-05	0.000196	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PPARG—thyroid cancer	1.64e-05	0.000192	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—PTEN—thyroid cancer	1.63e-05	0.000191	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—PTEN—thyroid cancer	1.63e-05	0.000191	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.52e-05	0.000178	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—RXRA—thyroid cancer	1.4e-05	0.000164	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTGS2—thyroid cancer	1.39e-05	0.000163	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—TPR—thyroid cancer	1.38e-05	0.000161	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.35e-05	0.000158	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—PTEN—thyroid cancer	1.33e-05	0.000155	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTGS2—thyroid cancer	1.29e-05	0.000151	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—PTEN—thyroid cancer	1.21e-05	0.000142	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—PTEN—thyroid cancer	1.12e-05	0.000132	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—AKT1—thyroid cancer	1.11e-05	0.000129	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.03e-05	0.00012	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—AKT1—thyroid cancer	9.4e-06	0.00011	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—AKT1—thyroid cancer	9.4e-06	0.00011	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PPARG—thyroid cancer	8.86e-06	0.000104	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—RXRA—thyroid cancer	8.65e-06	0.000101	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—AKT1—thyroid cancer	7.64e-06	8.94e-05	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—AKT1—thyroid cancer	7e-06	8.19e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTGS2—thyroid cancer	6.97e-06	8.16e-05	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—AKT1—thyroid cancer	6.48e-06	7.59e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—PTEN—thyroid cancer	6.08e-06	7.12e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PPARG—thyroid cancer	5.46e-06	6.39e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.3e-06	5.03e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—PTEN—thyroid cancer	3.75e-06	4.39e-05	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—AKT1—thyroid cancer	3.5e-06	4.1e-05	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—AKT1—thyroid cancer	2.16e-06	2.53e-05	CbGpPWpGaD
